Purpose:
To overcome resistance to antihormonal and HER2-targeted agents mediated by cyclin D1-CDK4/6 complex, we proposed an oral combination of the HER2 inhibitor tucatinib, aromatase inhibitor letrozole, and CDK4/6 inhibitor palbociclib (TLP combination) for treatment of HR./HER2. metastatic breast cancer (MBC).
Introduction:
Tumors that express hormonal receptors (HR) and amplified human epidermal growth factor
receptor 2 (HER2) comprise 11% of all breast cancer cases, with a higher frequency among young patients. In patients with young onset breast cancer (diagnosed at ≤45 years), HR+/HER2+ disease comprises 20% of cases and equals or exceeds the frequency of triple-negative disease. Visceral and CNS metastases are common in HR+/HER2+ metastatic breast cancer (MBC), and the associated morbidity and mortality is substantial.
Used by permission: Elena Shagisultanova, MD, PhD, University of Colorado Cancer Center